EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

Hilary J Longhurst, Karen Lindsay, Remy S Petersen, Lauré M Fijen, Padmalal Gurugama, David Maag, James S Butler, Mrinal Y Shah, Adele Golden, Yuanxin Xu, Carri Boiselle, Joseph D Vogel und 11 weitere

New England Journal of Medicine · 2024-02 · 390 (5) · 432-441

DOI: 10.1056/nejmoa2309149 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, 2024-02. Verfasst von Hilary J Longhurst und 22 weiteren Autor:innen. Beteiligte Einrichtung: From Te Toka Tumai, Department of Immunology, Auckland City Hospital (H.J.L., K.L.), and the Department of Medicine, University of Auckland (H.J.L.) …. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 196-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Intellia Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryCRISPR-Cas SystemsGene EditingAdultHumansAngioedemaComplement C1 Inhibitor ProteinDose-Response Relationship, DrugPlasma KallikreinTreatment OutcomeKallikreins

Substanzen

Complement C1 Inhibitor ProteinPlasma KallikreinKLKB1 protein, humanKallikreins

Autor:innen und Institutionen

  • From Te Toka Tumai, Department of Immunology, Auckland City Hospital (H.J.L., K.L.), and the Department of Medicine, University of Auckland (H.J.L.) - both in Auckland, New Zealand; the Department of Vascular Medicine,…

ORCID-Profile: David Lebwohl, Danny M Cohn

Förderung

  • Intellia Therapeutics

Zitieren

APA

Longhurst, H. J., Lindsay, K., Petersen, R. S., Fijen, L. M., Gurugama, P., Maag, D., Butler, J. S., Shah, M. Y., Golden, A., Xu, Y., Boiselle, C., Vogel, J. D., Abdelhady, A. M., Maitland, M. L., McKee, M. D., Seitzer, J., Han, B. W., Soukamneuth, S., Leonard, J., …, & Cohn, D. M. (2024). CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. New England Journal of Medicine, 390(5), 432-441. https://doi.org/10.1056/nejmoa2309149

Vancouver

Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, et al. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. New England Journal of Medicine. 2024;390(5):432-441. doi:10.1056/nejmoa2309149

BibTeX
@article{Longhurst2024,
  author = {Longhurst, Hilary J and Lindsay, Karen and Petersen, Remy S and Fijen, Lauré M and Gurugama, Padmalal and Maag, David and Butler, James S and Shah, Mrinal Y and Golden, Adele and Xu, Yuanxin and Boiselle, Carri and Vogel, Joseph D and Abdelhady, Ahmed M and Maitland, Michael L and McKee, Mark D and Seitzer, Jessica and Han, Bo W and Soukamneuth, Samantha and Leonard, John and Sepp-Lorenzino, Laura and Clark, Eliana D and Lebwohl, David and Cohn, Danny M},
  title = {CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {5},
  pages = {432--441},
  doi = {10.1056/nejmoa2309149}
}
Kostenlos starten →